Oscar Health's Q3 Margin Gains Prompt Reassessment of Bearish Thesis

What happened

Oscar Health raised its 2026 earnings outlook during the Q3 earnings call, citing improving medical costs and operating efficiencies that boosted margins, alongside expansion fueling 2027 growth ambitions. This update addresses the prior concern of MLR normalization toward the high end of guidance, as the improving medical cost trend suggests better-than-expected underwriting performance. However, the Zacks article omits specific figures on the ACA risk-adjustment accrual and net payable, which were the central risks flagged in the previous DeepValue report. The strong margin gains may partly stem from favorable reserve development or seasonal factors that could reverse, so the improvement needs to be validated by underlying details. The market likely reacted positively, but the structural question of risk-adjustment drag remains unanswered until the full 10-Q is reviewed.

Implication

Investors should interpret the raised guidance as a positive signal but remain vigilant about the quality of the margin improvement, as one quarter of favorable development does not negate the structural risk-adjustment volatility. The previous bearish scenario hinged on risk-adjustment accrual staying above 23% of direct premiums and net payable rising above $4.5B; if Q3 data show these metrics improving, the bear case weakens substantially. Conversely, if the margin gains are driven by non-repeatable items like prior-period reserve development, the stock may have overreacted and could correct. Membership expansion reverses a prior concern about post-subsidy enrollment decline, but it also introduces new medical cost risks if the new members' risk scores are not adequately captured. Investors should closely examine the 10-Q for the MLR trend, risk-adjustment accrual percentage, and net payable balance, and consider trimming positions if the stock has run up significantly without hard evidence of durable underwriting improvement.

Thesis delta

The prior POTENTIAL SELL thesis was based on risk-adjustment drag and MLR normalization; the Q3 earnings call suggests these risks may be easing, shifting the stance toward neutral but not yet bullish. The margin gains and raised outlook directly address the bear case's key concerns, but the lack of specific risk-adjustment numbers in the news article prevents a full confirmation. The updated view is to hold and monitor the upcoming 10-Q for evidence that risk-adjustment accrual is trending to ≤21% and net payable is stabilizing near $4B, which would support a more constructive outlook.